🔴 Goodrx is trading 5.3% down today with no clear catalyst identified

Goodrx is trading 5.3% down at $3.60, with no clear company-specific catalyst identified for the August 12, 2026 decline.

• No company-specific announcement, downgrade, or other catalyst directly explaining the decline was found; the broader market is higher, so macro sentiment does not clearly explain the drop.
• The decline reverses part of its recent rally. Investors may still be reassessing the August 5 earnings release: second-quarter revenue was $200.4 million and full-year guidance increased to $790–$805 million.
• Prescription-transactions revenue remained under pressure.